全文获取类型
收费全文 | 648篇 |
免费 | 25篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 8篇 |
妇产科学 | 18篇 |
基础医学 | 84篇 |
口腔科学 | 8篇 |
临床医学 | 34篇 |
内科学 | 89篇 |
皮肤病学 | 17篇 |
神经病学 | 13篇 |
特种医学 | 54篇 |
外国民族医学 | 1篇 |
外科学 | 103篇 |
综合类 | 18篇 |
预防医学 | 16篇 |
眼科学 | 17篇 |
药学 | 40篇 |
中国医学 | 13篇 |
肿瘤学 | 149篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 43篇 |
2021年 | 29篇 |
2020年 | 17篇 |
2019年 | 78篇 |
2018年 | 132篇 |
2017年 | 59篇 |
2016年 | 22篇 |
2015年 | 19篇 |
2014年 | 97篇 |
2013年 | 37篇 |
2012年 | 25篇 |
2011年 | 41篇 |
2010年 | 10篇 |
2009年 | 9篇 |
2008年 | 11篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 6篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1997年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 3篇 |
1978年 | 1篇 |
排序方式: 共有683条查询结果,搜索用时 15 毫秒
1.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献2.
Kensuke Kudou Hiroshi Saeki Yuichiro Nakashima Shun Sasaki Tomoko Jogo Kosuke Hirose Qingjiang Hu Yasuo Tsuda Koichi Kimura Ryota Nakanishi Nobuhide Kubo Koji Ando Eiji Oki Tetsuo Ikeda Yoshihiko Maehara 《American journal of surgery》2019,217(4):757-763
Background
There were few studies assessed the postoperative sarcopenia in patients with cancers. The objective of present study was to assess whether postoperative development of sarcopenia could predict a poor prognosis in patients with adenocarcinoma of esophagogastric junction, (AEG) and upper gastric cancer (UGC).Methods
Patients with AEG and UGC who were judged as non-sarcopenic before surgery were reassessed the presence of postoperative development of sarcopenia 6 months after surgery. Patients were divided into the development group or non-development group, and clinicopathological factors and prognosis between these two groups were analyzed.Results
The 5-year overall survival rates were significantly poorer in the development group than non-development group (68.0% vs. 92.6%, P?=?0.0118). Multivariate analyses showed that postoperative development of sarcopenia was an independent prognostic factor for poor overall survival (P?=?0.0237).Conclusions
Postoperative development of sarcopenia was associated with a poor prognosis in patients with AEG and UGC. 相似文献3.
Jin Wu Hao Wang Qing Li Qian-Ying Guo Si-Qi Tao Yu-Xian Shen Zheng-Sheng Wu 《Pathology, research and practice》2019,215(9):152523
Mammary carcinoma (MC) is one of most common malignancy in women, and ring finger protein 2 (RNF2) possesses various roles in vast human tumors. In MC tissues as well as in cell lines RNF2 exhibited high expression, had significant association with tumor size, lymph node status, TNM stage, patients’ poor survival, and promoted cell proliferation, colony formation, cell migration and invasion of MC cell lines which was mediated by downregulation of E-cadherin protein. These data reveal that RNF2 protein plays a vital role in the development of MC and may be a potential therapy target of MC. 相似文献
4.
5.
毒死蜱(chlorpyrifos,CPF)是一种广泛使用的有机磷农药,其对人类健康和生态系统的潜在风险已引起广泛关注。CPF主要通过抑制乙酰胆碱酯酶(AChE)发挥杀虫作用,但越来越多的研究表明,CPF的毒性作用远不止于此,也与氧化应激、炎症反应、 细胞死亡等多种生物学过程密切相关,因而可能导致神经退行性疾病、生殖发育障碍以及其他慢性健康问题。核因子红细胞2相关因子2(Nrf2)作为一种关键的抗氧化应激调节因子,具有显著的保护作用。本文旨在综述Nrf2在调节CPF诱导的氧化应激、神经毒性、细胞死亡和炎症反应中的作用机制,探讨其作为潜在治疗靶点的前景,以为开发新的CPF中毒治疗策略提供理论基础。 相似文献
6.
目的:探讨术前中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)对上皮性卵巢癌患者预后的评估价值。方法:收集2005年11月至2012年12月在天津市中心妇产科医院初治且经手术治疗的153例卵巢良性肿瘤和206例上皮性卵巢癌患者的临床病理资料,比较术前NLR和PLR在卵巢良恶性肿瘤的区别,根据统计学方法选取NLR和PLR临界值,分析NLR和PLR与上皮性卵巢癌临床病理因素的关系。通过单因素及多因素分析评估术前NLR和PLR对患者术后生存的影响。结果:术前NLR和PLR水平在上皮性卵巢癌中明显高于卵巢良性肿瘤。选取NLR=2.62和PLR=173分别作为临界值。单因素分析结果显示,FIGO分期晚、中-低分化、腹水、脉管癌栓、CA125≥35、NLR≥2.62、PLR≥173是影响患者术后无病生存期(DFS)的危险因素(P0.05);FIGO分期晚、腹水、脉管癌栓、CA125≥35、PLR≥173是影响患者术后总生存期(OS)的危险因素(P0.05)。多因素分析显示,FIGO分期晚、NLR≥2.62、脉管癌栓是上皮性卵巢癌患者DFS的独立危险因素(P0.05)。结论:NLR和PLR方便测得且价格便宜,对卵巢癌的预后有一定的评估价值。 相似文献
7.
Yang Liu Hongyan Wang Sen Yang Yuanyuan Yang Yufeng Wu Zhen He Shuxiang Ma Yuqing Mo Haiyang Chen Qiming Wang Hong Ge 《Journal of thoracic disease》2022,14(6):2254
BackgroundEpidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are currently recognized as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Clinically found patients with different EGFR mutational status have different prognosis.MethodsA retrospective cohort study was performed to explore the relationship between EGFR mutations and abundance with patient survival by using patient data from the Affiliated Cancer Hospital of Zhengzhou University between January 2013 and November 2016. All patients involved in the present study had sensitive EGFR mutations [either exon 19 deletion (DEL) or exon 21 L858R] and treated by EGFR-TKIs. They were followed up every three months until lost or dead. Mutation abundance was calculated as the copies of EGFR mutation divided by copies of EGFR locus, and the cut-off values for 19DEL and L858R were 4.9% and 9.5%, respectively.ResultsTotal of 236 patients were included, comprising 116 (49.2%) patients with 19DEL mutation and 120 (50.8%) patients with L858R mutation. The median follow-up duration was 23.2 months (95% CI: 14.9–26.7 months). Overall survival (OS) was significantly longer in patients with 19DEL mutation (20.9 months, 95% CI: 17.7–24.1 months versus 17.0 months, 95% CI: 14.4–19.6 months in patients with L858R; P=0.008) and in patients with high mutation abundance (20.9 months, 95% CI: 18.3–23.5 months versus 13.0 months, 95% CI: 10.3–15.7 months in patients with low mutation abundance; P<0.001). Multivariate Cox regression including age, performance status and tumor stage revealed that longer OS was independently associated with 19DEL mutation (HR: 0.48, 95% CI: 0.39–0.67, P=0.033) and high mutation abundance (HR: 0.62, 95% CI: 0.50–0.79, P=0.027).ConclusionsEGFR mutation types and abundance was associated with the patients’ survival which might be used to predict the efficacy of targeted therapy by EGFR-TKIs. 相似文献
8.
Claudia Fumarola Mara A. Bonelli Pier Giorgio Petronini Roberta R. Alfieri 《Biochemical pharmacology》2014
While PI3K/AKT/mTOR pathway is altered in a variety of cancers including non small cell lung cancer, abnormalities in this pathway are more common in squamous cell lung carcinoma than in adenocarcinoma of the lung. Moreover, aberrant activation of PI3K/AKT/mTOR pathway is one of the mechanisms of acquired resistance to EGFR-TK inhibitors in patients with adenocarcinoma carrying EGFR activating mutations. 相似文献
9.
Srivastava G Pilkington A Nallala D Polson DW Holt E 《Archives of gynecology and obstetrics》2007,276(5):555-557
Objective Ogilvies syndrome (OS) is a rare condition in obstetrics but occurs most commonly after caesarean section. Mortality rates
from OS can be as high as 36–50% when bowel perforation or ischemia develops which highlights the early recognition of this
condition. Early diagnosis is therefore essential to prevent serious morbidity and mortality.
Conclusion We, therefore report a case of OS after caesarean section in which early detection by senior clinicians resulted in successful
management of the condition and an excellent outcome. 相似文献
10.
【目的】 探讨硫化氢单独及与顺铂联用对骨肉瘤细胞生长的影响及其可能机制?【方法】 分别用0.2?0.4?0.6?0.8?1.0?2.0?3.0?4.0?5.0 mmol/L NaHS(硫化氢载体)单独或与20 mg/L顺铂共同作用骨肉瘤U2OS细胞24 h,CCK-8比色法法检测细胞存活率;分别用0.4及1.0 mmol/L NaHS作用骨肉瘤U2OS细胞24 h,1.0 mmol/L NaHS单独或与20 mg/L顺铂联用作用骨肉瘤U2OS细胞24 h,细胞单克隆形成法检测各组单克隆数;1.0 mmol/L NaHS与20 mg/L顺铂共同作用骨肉瘤U2OS细胞24 h,Western-Blot法检测Bcl-2?Bax?NFκB蛋白的表达?【结果】硫化氢对U2OS细胞生长的影响:0.2?0.4?0.6?0.8 mmol/L NaHS作用U2OS细胞24 h,细胞存活率与对照组比较,差异无统计学意义(P > 0.05); 1?2?3?4?5 mmol/L NaHS作用U2OS细胞24 h,细胞存活率分别为(90.01 ± 7.49)%?(88.00 ± 4.12)%?(87.26 ± 4.05)%?(85.40 ± 4.39)%和(82.99 ± 4.65)%,与对照组比较,能不同程度抑制U2OS细胞的生长(P 0.05)?NaHS与顺铂联用对骨肉瘤细胞的影响:分别用0.8?1?2?3?4?5 mmol/L NaHS联合20 mg/L顺铂共同作用U2OS细胞24 h,细胞存活率分别为(54.13 ± 4.03)%?(54.09 ± 1.13)%?(50.37 ± 4.56)%?(41.44 ± 3.95)%?(40.00 ± 4.34)%和(36.35 ± 3.90)%,与单用顺铂组(59.76 ± 3.15%)比较,存活率下降(P < 0.05)?NaHS+顺铂组细胞单克隆数为231.00 ± 13.52,与顺铂组(285.67 ± 11.59)比较,细胞单克隆数下降(P < 0.01); NaHS+顺铂组NFκB蛋白表达及Bcl-2/Bax蛋白表达比值较顺铂组下降?【结论】 1 mmol/L浓度以上的NaHS能抑制骨肉瘤细胞的生长,0.8 mol/L浓度以上的NaHS通过减少NFκB入核,增加细胞的凋亡,从而增强顺铂对骨肉瘤细胞的抑制作用? 相似文献